DavidHenryAggenMDPhD

Assistant Attending, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center

Overview of Dr. Aggen

Dr. David Aggen is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from University of Illinois College of Medicine at Chicago and has been in practice 6 years. He is experienced in prostate cancer, kidney cancer, and bladder cancer. He has more than 20 publications and over 500 citations in bladder, kidney, and prostate cancer.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(904) 584-3558

Education & Training

Detroit Medical Center/Wayne State UniversityResidency, Hematology and Medical Oncology, 2013 - 2016
University of Illinois College of Medicine

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 2016 - 2025
PA State Medical License 2023 - 2024
MI State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

2023 Castle Connelly Top Doctors 2023
ASCO Career Development Award American Society of Clinical Oncology, 2021
ASCO Young Investigator Award American Society of Clinical Oncology, 2017

Clinical Trials

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer Start of enrollment: 2022 Jun 02
Recruiting
Phase 2
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Start of enrollment: 2019 Aug 20
Recruiting
Phase 1
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Start of enrollment: 2015 Dec 01
Recruiting

Publications & Presentations

PubMed

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic
European Urology. 2025-01-01
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies.
Michael V Gormally, Monica F Chen, Anne Marie Noronha, Kristalla Panageas, Maggie Reynolds
JAMA Oncology. 2024-11-27
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, Nivedita Chowdhury, Aditya Pratapa
Clinical Cancer Research. 2024-11-15

Lectures

Preclinical development of combination therapy targeting the dominant cytokine interleukin-1Î² for renal cell carcinoma.
2019 ASCO Annual Meeting - 6/1/2019

Grant Support

ASCO Young Investigator Award 2018Conquer Cancer Foundation2018–2019